Aug. 31, 2020 – Following the Democratic and Republican convention attacks on big pharma and President Trump’s acceptance speech for his party’s nomination for re-election – in which he claimed to have already taken effective action to lower prescription drug prices through Executive Orders – the Pharmaceutical Research and Manufacturers of America (PhRMA) is making […]
Read more
July 27, 2020 – The four Executive Orders signed by President Trump on Friday were designed to address drug pricing concerns, but their combined impact is modest and they are “unlikely to have any immediate effect,” according to Coalition for Healthcare Communication Executive Director Jon Bigelow. However, they do “give the president talking points for […]
Read more
Sept. 20, 2019 – Although the House proposal unveiled by House Speaker Nancy Pelosi (D-Calif.) to combat high drug prices would cap Medicare drug prices based on the average price in six developed countries, require that the federal government and drug companies negotiate prices for up to 250 of the most expensive prescription drugs, mandate […]
Read more
By Michael Parenti, Senior Engagement Strategist, Saatchi & Saatchi Wellness Feb. 1, 2019 — On Oct. 25, 2018, the Centers for Medicare and Medicaid Services (CMS) issued an advance notice of proposed rulemaking (ANPRM) to test whether phasing down the Medicare payment amount for selected Part B drugs to more closely align with international prices […]
Read more